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Sphingosine-1-phosphate receptor 3 promotes
leukocyte rolling by mobilizing endothelial
P-selectin
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Sphingosine-1-phosphate (S1P) participates in inflammation; however, its role in leukocyte
rolling is still unclear. Here we use intravital microscopy in inflamed mouse cremaster muscle
venules and human endothelial cells to show that S1P contributes to P-selectin-dependent
leukocyte rolling through endothelial S1P receptor 3 (S1P3) and Gaq, PLCb and Ca2þ . Intra-
arterial S1P administration increases leukocyte rolling, while S1P3 deficiency or inhibition
dramatically reduces it. Mast cells involved in triggering rolling also release S1P that mobilizes
P-selectin through S1P3. Histamine and epinephrine require S1P3 for full-scale effect
accomplishing it by stimulating sphingosine kinase 1 (Sphk1). In a counter-regulatory manner,
S1P1 inhibits cAMP-stimulated Sphk1 and blocks rolling as observed in endothelial-specific
S1P1
 / mice. In agreement with a dominant pro-rolling effect of S1P3, FTY720 inhibits rolling
in control and S1P1
 / but not in S1P3 / mice. Our findings identify S1P as a direct and
indirect contributor to leukocyte rolling and characterize the receptors mediating its action.
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S
phingosine-1-phospate (S1P) is a bioactive lysophospholi-
pid with important functions in the immune and cardio-
vascular systems and has been implicated in different
aspects of inflammatory disorders1. High S1P concentrations
have been measured locally at inflammatory sites2,3, where it is
generated by sphingosine kinases activated through inflammatory
cytokines, lipopolysaccharide (LPS) or thrombin. This suggests a
role for S1P in the propagation of the inflammatory response4. In
contrast, S1P opposes the pathologically increased endothelial
permeability common to all inflammatory processes and prevents
vascular leakage caused by LPS, thrombin or platelet-activating
factor5–7. There is also evidence both for stimulatory and
inhibitory effects of S1P on leukocyte recruitment in
inflammation. In favour of a pro-inflammatory role, exogenous
S1P induces endothelial vascular cell adhesion molecule 1
(VCAM-1) and E-selectin, while endogenous S1P mediates the
stimulatory effect of tumor-necrosis factor (TNF)-a and LPS on
adhesion molecules, which is suppressed by S1P1 short interfering
RNA8–10. In support, chronic overexpression of sphingosine
kinase 1 augments VCAM-1 and E-selectin expression and
enhances neutrophil adhesion after TNF-a11. In contrast, both
S1P and S1P1 agonists have been demonstrated to inhibit TNF-a-
induced endothelial adhesion molecule expression and adherence
of inflammatory cells by interfering with endothelial NF-kB and
stimulating nitric oxide production12–14. Several explanations
have been put forward for these apparent discrepancies such as
the assumption that S1P receptors may be differentially expressed
among endothelial beds, and that the wide range of S1P
concentrations employed in the individual studies may have
led to contrary effects as observed for S1P in other systems15.
However, in all these studies the focus has been on S1P1, while
any involvement of S1P receptor 3 (S1P3) has not been addressed.
In contrast to the effects of S1P on firm leukocyte adhesion, its
role on leukocyte rolling—the crucial initial step of inflammatory
cell recruitment—has not been investigated in detail. Recently,
sphingosine kinase-1 has been shown to contribute to histamine-
induced leukocyte rolling, but the mechanism of action has
remained elusive16. In general, leukocyte capture and rolling is
mediated by the selectin family of adhesion molecules consisting of
three selectins: L-, E- and P-selectin17,18. L-selectin is expressed on
most leukocytes and mediates leukocyte capture and rolling
through binding to selectin ligands found on high endothelial
venules of lymphoid organs. E-selectin and P-selectin are expressed
on the activated vascular endothelium during inflammation and
mediate rolling through binding to carbohydrate moieties of
selectin ligands on leukocytes17,18. Among the selectins, P-selectin
contributes to disease pathology in many experimental models
including myocardial and renal infarction, thrombosis, stroke,
atherosclerosis, cerebral malaria and sickle cell disease19, as has
been shown using P-selectin-blocking antibodies and knockout
strategies in mouse, feline and baboon models20–23.
We have recently identified leukocyte recruitment defects in
S1P3 / mice in atherosclerosis and peritoneal inflammation that
were caused by both haematopoietic and non-haematopoietic
S1P3 deficiency3. In addition, treatment with the S1P analogue
FTY720 severely reduced leukocyte recruitment into the inflamed
peritoneum3. Currently, it is controversial if S1P in general and
S1P3 in particular affect leukocyte rolling.
In this study, we address this issue by studying P-selectin-
dependent leukocyte rolling in surgically prepared post-capillary
venules of the mouse cremaster muscle in vivo. These studies are
complemented by experiments in a novel in vitro system to
investigate the mechanisms of the rapid P-selectin mobilization
that occurs within minutes in endothelial cells and stems from the
exocytosis of Weibel–Palade bodies. Our results demonstrate a
unique role of S1P and S1P3 in P-selectin-dependent rolling both
by direct action as well as by contributing to P-selectin
mobilization by other agonists.
Results
S1P3 deficiency and inhibition reduce leukocyte rolling. To
examine whether S1P3 plays a role in P-selectin-dependent
leukocyte rolling in vivo, we employed intravital microscopy to
monitor rolling in post-capillary venules of the surgically
exteriorized mouse cremaster muscle24,25. In this model,
profound spontaneous leukocyte rolling is induced by the
surgical preparation of the cremaster (hence termed trauma),
which exclusively depends on the rapid mobilization of P-selectin
from endothelial Weibel–Palade bodies to the luminal surface
in its initial phase (o45 min after exteriorization of the cremaster
muscle)17,26–28. Elegant studies from the 1990s have shown
that the endothelial P-selectin mobilization is in large part caused
by activation products of tissue mast cells released upon
mechanical manipulation during surgery29. Here we employed
this model to study leukocyte rolling in S1P3 / mice and
observed that their rolling flux fraction (as a measure of rolling)
was greatly diminished compared with C57Bl6 controls (Fig. 1a).
Neither microvascular/haemodynamic conditions nor leukocyte
rolling velocities differed between groups excluding any bias
by these variables (Table 1 and Supplementary Fig. 1). Systemic
application of a P-selectin-blocking antibody completely
abrogated leukocyte rolling in both genotypes (Fig. 1a)
confirming the dependence of rolling on P-selectin in this
model and both genotypes, respectively. In addition, whole-
mount immunohistochemistry for intravascular P-selectin
clearly showed the appearance of luminal P-selectin in controls
but not in S1P3 / mice (Fig. 1a). Of note, S1P3-deficient
leukocytes had no intrinsic defect in rolling as we determined
in an ex vivo flow chamber system30, where blood was diverted
from the carotid artery into microflow chambers coated with
immobilized murine P-selectin31 (Fig. 1b). We also assessed
cell surface expression of P-selectin glycoprotein ligand-1 as
the main, if not only, functional P-selectin ligand on neutrophils,
and found no differences between S1P3 / and C57Bl6 mice
(Supplementary Table 1).
We next tested the effect of TY-52156, a highly specific S1P3
inhibitor32, on leukocyte rolling in C57Bl6 mice. As TY-52156 is
not commercially available, we synthesized it according to
published protocols32 and confirmed its specificity for S1P3
in comparison to S1P1 (Supplementary Figs 2,3). Intraperitoneal
administration of TY-52156 (1.25 mg per kg body weight) 30 min
before the experiment leads to a dramatic reduction in leukocyte
rolling (Fig. 1c). To test whether the opposite–stimulation of the
vasculature by exogenous S1P–would increase rolling, we injected
S1P directly into the carotid artery (30 mg per kg body weight) in
C57Bl6 mice and measured leukocyte rolling immediately
thereafter. Indeed, we observed that rolling was dramatically
enhanced by S1P (Fig. 1d).
S1P3 induces P-selectin and rolling via Gq, PLC and Ca2þ .
Exposure of cell surface P-selectin on luminal endothelial cells is
the prerequisite for trauma-induced leukocyte rolling in the
experimental model we have used here17,26–28. To pursue the
mechanism by which S1P and S1P3 affect P-selectin mobilization,
we established an assay for quantitative assessment of cell surface
P-selectin using flow cytometry in human umbilical endothelial
cells (HUVECs) as the only system applicable for such studies.
Nevertheless, HUVECs are still extremely difficult to work with in
respect to studying P-selectin as they express it only under certain
culture conditions and lose ability for mobilizing it already after
one to two passages. Nevertheless, we successfully established the
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assay and validated it extensively using histamine and H1 and H2
receptor antagonists (Supplementary Fig. 4). Using this assay, we
observed that stimulation of HUVEC with 1mM S1P resulted in an
extremely rapid (within 5 min) appearance of P-selectin on the cell
surface (Fig. 2a). In contrast, the agonist of the S1P1 receptor
SEW2871 was ineffective (Fig. 2a). In agreement with a role of S1P3
in the process, preincubation with 10 mM TY-52156 for 30 min
substantially diminished P-selectin mobilization by S1P (Fig. 2a).
We then addressed the signalling pathways downstream of
S1P/S1P3 responsible for P-selectin mobilization. Phospholipase
C (PLC) and Ca2þ are known to play a role in the exocytosis of
Weibel–Palade bodies33, and S1P has been shown to activate PLC
in CHO cells overexpressing S1P3 (ref. 34,35). Thus, we added the
PLC inhibitor U73122 (3 mM) 2 min before S1P stimulation and
observed a clear reduction in P-selectin mobilization (Fig. 2b). To
address the role of Ca2þ , we depleted internal Ca2þ pools by
adding thapsigargin (3 mM) for 5 min before stimulation with
S1P, while simultaneously preventing the extracellular Ca2þ
influx by EGTA (3 mM) added for the last minute. This treatment
substantially suppressed P-selectin mobilization (Fig. 2b).
Although S1P3 couples to three G proteins (Gq, Gi and G12/13),
the predominant signalling pathway it exercises is through Gq (ref.
36). To test for an involvement of Gq in leukocyte rolling in our
model in general, we employed mice deficient for Gq in endothelial
cells on a global G11-deficient background (Gq/11 / mice)37.
We observed them to have a substantial reduction in leukocyte
rolling (Fig. 2c). Administration of TY-52156 did not reduce
rolling any further in Gq/11 / mice (Fig. 2c), suggesting that
under normal circumstances S1P3 enhances rolling through Gq.
FTY720 and S1P lyase blockade suppress rolling by impacting
on S1P3. On the basis of our results so far, we hypothesized that
downregulation of S1P3 by FTY720 would inhibit leukocyte
rolling to a similar extent as does S1P3 deficiency or a S1P3
inhibitor. Furthermore, if S1P3 were the only receptor inducing
P-selectin mobilization by S1P, FTY720 should not decrease
rolling any further in S1P3 / mice. Indeed, administration of
1.25 mg per kg FTY720 either 30 min or 24 h before the experi-
ment dramatically attenuated leukocyte rolling (Fig. 3a). In
agreement with our second hypothesis, we observed no additional
inhibition of rolling by FTY720 in S1P3 / mice (Fig. 3b).
Finally, treatment with the S1P lyase inhibitor 4-deoxypyridoxine
(DOP) that elevates plasma and tissue S1P and downregulates all
S1P receptors38 also inhibited rolling (Fig. 3c). Rolling velocities
did not differ significantly between the experimental groups
(Supplementary Fig. 1), and P-selectin-mediated rolling was
independent of putative DOP effects on plasma or leukocytes as
no differences in rolling were observed on immobilized P-selectin
(Supplementary Fig. 5).
We then went further to examine the effect of FTY720 on
P-selectin mobilization in vitro. Pretreatment of HUVEC with the
active, phosphorylated form of FTY720 (pFTY720, 10 mM for
30 min) almost completely abolished S1P-induced mobilization of
P-selectin (Fig. 3d). PhosphoFTY720 itself (1mM) had only a
minor, almost negligible effect on P-selectin compared with 1 mM
S1P after 5 min and no effect at all after 30 min (a time when the
S1P effect was still clearly visible; Fig. 3d). This may seem
surprising in light of the agonistic effect of pFTY720 known for
all S1P receptors except S1P2 before their subsequent cell surface
downregulation. However, we have previously shown that
pFTY720 activates only the Gi and not the Gq signalling pathway
of S1P3 and also inhibits Gq-transmitted S1P3 signalling by
native S1P39. Here we observed something very similar in respect
to P-selectin: addition of a 10-fold higher concentration of
pFTY720 simultaneously with S1P resulted in a clear inhibition of
S1P-induced P-selectin mobilization (Fig. 3d). In agreement,










































































































C57Bl6 + S1P3 inhibitor
Figure 1 | Leukocyte rolling is reduced in S1P3
 / mice and after S1P3 blockade, respectively, and is enhanced by S1P administration. Leukocyte rolling
was quantified in postcapillary venules of the cremaster muscle of (a) S1P3
 / mice (n¼ 5) and C57Bl6 controls (n¼ 6). Rolling was abolished by systemic
injection of a P-selectin-blocking antibody in both groups. Middle: representative snap shot images of rolling leukocytes (arrows) are shown. Right:
representative whole-mount immunohistochemistry for P-Selectin after in vivo injection of an anti-P-selectin antibody (left: no staining in uninjured
cremaster, right: luminal P-selectin staining in the contralateral exteriorized cremaster). Scale bar, 40 mm. (b) Unaltered rolling of S1P3 / leukocytes on
immobilized P-selectin. Microflow chambers were coated with recombinant murine P-selectin and perfused with arterial blood diverted from the carotid
artery of C57Bl6 and S1P3
 / mice (n¼ 3 each) for the indicated times. The number of rolling cells was quantified per field of view (FOV). (c) Rolling in
C57Bl6 mice with (n¼4) and without (n¼ 5) the S1P3 inhibitor TY-52156 (1.25 mg kg 1 intraperitoneally (i.p.) 30 min before experiment). (d) Rolling in
C57Bl6 mice at baseline and immediately after S1P injection into the carotid artery (30mg kg 1, n¼ 5). Quantitative data are presented as mean±s.e.m.
Significance was established using a Wilcoxon rank sum test or a paired two-tailed Student’s t-test. In all experiments: *Po0.05; **Po0.01; ***Po0.001.
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— S1P3-overexpressing CHO cells — followed by removal and
subsequent (30 min later) S1P stimulation abolished S1P3-
dependent signalling such as Erk MAPK activation
(Supplementary Fig. 6).
S1P3 conveys part of the P-selectin mobilization by histamine.
P-selectin mobilization and consecutive leukocyte rolling in the
trauma-stimulated cremaster muscle venules that we have


























































































3.5 * C57Bl6Gq endothelial –/–
Gq endothelial –/– + S1P3inhibitor
Figure 2 | S1P mobilizes P-selectin in endothelial cells and induces rolling through a S1P3/Gq/PLC/Ca
2þ pathway. (a) HUVECs were stimulated with
S1P (1mM) for 5 min in the presence or absence of the S1P3 inhibitor TY-52156 (10 mM) or stimulated with the S1P1 agonist SEW2871 (1 mM). P-selectin
surface expression was analysed using flow cytometry. Data shown are from at least three independent experiments. Representative histogram is shown as
inset. (b) HUVECs were stimulated with S1P (1mM) in the presence or absence of U73122 (3 mM for 2 min) or thapsigargin (3 mM for 5 min) in combination
with EGTA (3 mM for the last 1 min). P-selectin was analysed using flow cytometry 5 min after the addition of S1P. Data shown are from at least three
independent experiments. (c) Leukocyte rolling was quantified in postcapillary venules of the cremaster muscle of Gq/11 / mice (Gq endothelial  / )
in the presence (n¼4) or absence (n¼ 5) of the S1P3 inhibitor TY-52156 (1.25 mg kg 1 i.p. 30 min before the experiment) and in controls (n¼4).
P-selectin-blocking antibody was injected to confirm complete dependence of rolling on P-selectin. Quantitative data are presented as mean±s.e.m.
Significance was established using a paired two-tailed Student’s t-test or a Kruskal–Wallis analysis of variance (ANOVA) on ranks. *Po0.05; **Po0.01.
Table 1 | Haemodynamic parameters of mouse cremaster muscle experiments.
Mouse strain Treatment Fig. Mice (n) Venules Diameter (lm) Centreline velocity (lm s 1) Shear rate (s 1) WBC ( 103 ll 1)
C57Bl6 None 1a 6 21 30.0±1.1 1,876±215 1,562±160 5,704±622
S1P3
 / 5 20 28.8±1.4 1,885±182 1,449±203 8,060±983
C57Bl6 None 1c 5 16 33.6±1.6 2,181±324 1,693±319 6,659±192
C57B6 S1P3i 4 17 29.9±1.0 1,861±183 1,614±138 5,808±633
C57Bl6 None 1d 5 5 34.9±1.6 1,638±406 1,150±270 5,032±613
S1P 5 5 34.0±1.8 1,427±408 1,006±248 4,144±367
C57Bl6 None 2c 4 17 29.3±1.9 2,635±195 2,303±188 5,633±254
Gq/11
 / None 5 22 30.8±1.3 2,973±162 2,445±160 6,405±163
Gq/11
 / S1P3i 4 22 29.7±1.2 1,623±113* 1,367±93* 3,348±1,076
C57Bl6 None 3a 5 26 33.4±1.1 2,017±163 1,524±131 7,043±899
FTY 30 min 6 36 34.3±0.8 1,857±127 1,380±94 4,270±203
FTY 24 h 6 35 32.5±1.0 1,540±100 1,178±71 1,110±152*
C57Bl6 Nonew 3b 6 21 30.0±1.1 1,876±215 1,562±160 5,704±622
FTY 30 min 8 32 29.4±0.6 2,419±203 2,033±175 7,147±343
S1P3
 / Nonew 5 20 28.8±1.4 1,885±182 1,449±203 8,060±983
FTY 30 min 5 19 29.2±0.6 2,384±196 2,014±185* 6,998±937
C57Bl6 Normal diet 3c 4 17 30.3±0.7 1,894±185 1,510±132 4,819±1,090
DOP diet 5 23 30.3±0.9 1,839±186 1,476±125 2,415±297
C57Bl6 None 4c 4 16 33.6±1.0 1,613±145 1,178±101 8,143±548
Sphk1 / 4 15 33.7±1.7 1,709±217 1,420±241 7,760±299
C57Bl6 Nonez 5e 5 26 33.4±1.1 2,017±163 1,524±131 7,043±899
Forskolin 5 21 30.4±1.2 2,143±163 1,768±147 3,382±579*
S1P1
SCL-Cre-ERT Cre None 7a 9 32 30.1±0.8 1,778±153 1,465±127 3,250±567
S1P1
SCL-Cre-ERT Creþ 9 35 29.1±0.6 1,849±172 1,546±136 2,238±289
S1P1
SCL-Cre-ERT Cre Noney 7b 9 32 30.1±0.8 1,778±153 1,465±127 3,250±567
FTY720 3 12 27.7±0.9 1,675±209 1,488±184 2,280±742
S1P1
SCL-Cre-ERT Creþ Noney 9 35 29.1±0.6 1,849±172 1,546±136 2,238±289
FTY720 4 16 27.8±0.9 2,237±232 1,999±213 3,015±459
DOP, 4-deoxypyridoxine; S1P, sphingosine-1-phosphate; SCL, stem cell leukaemia; WBC, white blood cell.
*Po0.05 versus respective control (‘none’).
wData are identical to Fig. 1a (‘none’).
zData are identical to Fig. 3a (‘none’).
yData are identical to Fig. 7a (‘none’).
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products of tissue mast cells activated upon mechanical manip-
ulation during surgery29. Of these products, histamine accounts
for approximately half of the effect on rolling as elegantly shown
using H1 and H2 histamine receptor antagonists29. Recently, Sun
et al.16 demonstrated that histamine superfusion of the cremaster
muscle induces leukocyte rolling dependent on sphingosine
kinase 1 (Sphk1), but the mechanism has remained
unidentified. We asked the question whether S1P3 might be
involved in histamine-induced P-selectin mobilization. To tackle
this, we first titrated down the histamine concentration from
25 mM (routinely used in the vast majority of the literature) to a
100-fold lower concentration of 0.25 mM (Fig. 4a). This much
lower histamine concentration still leads to a substantial
P-selectin mobilization in HUVEC within 5 min (Fig. 4a). The
well-characterized sphingosine kinase inhibitor 4-[[4-(4-
chlorophenyl)-2-thiazolyl]amino]-phenol (SKi, 25 mM (ref. 40))
suppressed P-selectin mobilization at both histamine
concentrations, but was particularly effective at the lower one
(Fig. 4a). Remarkably, administration of exogenous S1P in
addition to SKi partially restored P-selectin mobilization by
histamine (Fig. 4a), arguing for a S1P receptor conveying Sphk1-
mediated, histamine-dependent P-selectin mobilization. We then
tested whether the responsible S1P receptor may be S1P3. Indeed,
preincubation with the S1P3 inhibitor TY-52156 for 30 min
dramatically reduced P-selectin mobilization by 0.25 mM
histamine (Fig. 4b). Thus, the reduction of histamine to lower
and presumably more physiological concentrations in our model
allowed us to assign part of its P-selectin-mobilizing effect to the
engagement of S1P3 through endogenous Sphk1-generated S1P.
Finally, we observed that leukocyte rolling was substantially
reduced in cremaster muscle venules of Sphk1 / mice in vivo
compared with C57Bl6 controls (Fig. 4c). Altogether, our data
suggest that part of the histamine effect on P-selectin-mediated
rolling is mediated by its activation of Sphk1, production of
endogenous S1P and subsequent stimulation of P-selectin
mobilization by endothelial S1P3.
cAMP induces P-selectin and rolling through Sphk1 and S1P3.
Several other agents besides histamine such as thrombin, vaso-
pressin receptor agonists, purine nucleotides and epinephrine are
well known to induce rapid P-selectin mobilization41. Many of
them elevate intracellular cAMP through activation of the
Gs/adenylate cyclase (AC) pathway; however, the exact
mechanisms leading to subsequent P-selectin mobilization are
not entirely clear. In our hands, epinephrine (9 mM) potently
induced P-selectin mobilization in HUVEC (Fig. 5a).
Remarkably, the S1P3 inhibitor TY-52156 substantially albeit
not entirely suppressed epinephrine-induced P-selectin
mobilization (Fig. 5a). Assuming that the cAMP/AC pathway is
involved, we applied forskolin (10 mM) as an established tool to
directly stimulate AC. Indeed, forskolin potently mobilized
P-selectin mobilization in HUVEC (Fig. 5b). Interestingly, this
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Figure 3 | FTY720 inhibit leukocyte rolling and P-selectin mobilization by S1P by interfering with S1P3. Reduced rolling after S1P lyase inhibition.
(a) Leukocyte rolling in C57Bl6 mice treated without (n¼ 5) or with 1.25 mg kg 1 FTY720 i.p. either 30 min or 24 h (n¼6 each) before
experiment. (b) Leukocyte rolling in C57Bl6 (n¼8) and S1P3 / mice (n¼ 5) treated with 1.25 mg kg 1 i.p. FTY720 30 min before experiment. Untreated
C57Bl6 and S1P3
 / mice served for comparison (n¼ 6 and 5). (c) Leukocyte rolling in C57Bl6 mice treated with (n¼ 5) and without the S1P lyase inhibitor
DOP (n¼4). Top: whole-mount immunohistochemistry for P-Selectin after in vivo injection of an anti-P-selectin antibody shows the lack of P-selectin
mobilization in the exteriorized traumatized cremaster (right) compared with the contralateral uninjured one (left). Scale bar, 40 mm. (d) HUVECs were
stimulated with S1P (1 mM) or pFTY720 (1mM) for 5 and 30 min with and without pFTY720 preincubation (1 mM) for 30 min. In some experiments,
pFTY720 (10 mM) and S1P (1 mM) were added simultaneously for 5 min. ‘þ þ þ ’ indicates the 10-fold higher pFTY720 concentration that was added
simultaneously with S1P in this case. P-selectin surface expression was analysed by flow cytometry. Data are from three independent experiments.
Quantitative data are presented as mean±s.e.m. Significance was established using a Kruskal–Wallis ANOVA on ranks or a Wilcoxon rank sum test, or a
paired two-tailed Student’s t-test (d). Po0.05; **Po0.01; ***Po0.001; yo0.05 between S1P3 / and S1P3 / with FTY720 in (b).
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data suggested that a mechanism involving AC activation and
relying on S1P3 is in part responsible for P-selectin mobilization
by cAMP-generating agents such as epinephrine and forskolin.
Forskolin has been shown to activate Sphk1 in
pheochromocytoma cells42. We thus hypothesized that this may
be the case in endothelial cells as well. Thus, we determined
enzymatic Sphk1 activity after forskolin stimulation by measuring
the conversion of C17-sphingosine to C17-S1P using mass
spectrometry. Indeed, C17-S1P production was clearly increased
after forskolin (10 mM) treatment of HUVEC for 30 min (Fig. 5c).
To explore the consequences for P-selectin mobilization, we
employed forskolin and the nondegradable cAMP analogue cpt-
cAMP, respectively, to activate Sphk and added the Sphk
inhibitor SKi. Indeed, both forskolin (10 mM) and cpt-cAMP
(0.3 mM) induced P-selectin mobilization, and in both cases SKi
treatment substantially reduced it (Fig. 5d). Finally, we sought to
reproduce these findings at the level of leukocyte rolling in vivo
and applied forskolin (1.3 mg kg 1) intraperitoneally in our
cremaster model. In agreement with its induction of P-selectin
in vitro, forskolin clearly stimulated leukocyte rolling in vivo
(Fig. 5e). In summary, these data have identified a novel cAMP-
dependent mechanism of P-selectin mobilization that acts
through Sphk1 activation and employs subsequent S1P3
signalling.
Mast cell-derived S1P induces P-selectin in HUVEC via S1P3.
According to previous studies, histamine release from mast cells
accounts for half of the leukocyte rolling in the cremaster model
that by itself is completely mast cell-dependent29. Although S1P is
not contained in mast cell granules, mast cell can release large
amounts of S1P when allergically stimulated43–45. Thus, we
hypothesized that tissue mast cells may be another source of S1P
in our model thereby causing P-selectin mobilization and rolling.
Physical stimuli such as pressure and temperature are known to
induce mast cell activation in vitro and in vivo46,47. As surrogate
for the physical stimulus of mechanical mast cell manipulation
occurring during cremaster muscle exteriorization, we employed
transient exposure of isolated peritoneal mast cells to a
temperature of 53 C for 2 min as commonly employed to
activate mast cell without adverse effects on viability46,47. We
then added the mast cell supernatants immediately to HUVEC
and measured P-selectin surface expression (Fig. 6). To exclude
effects of histamine released under these conditions, we added
diphenhydramine and cimetidine in concentrations sufficient to
completely block P-selectin mobilization by 0.25 mM histamine
(Supplementary Fig. 4). The mast cell supernatants induced an
impressive four- to fivefold increase in cell surface P-selectin
expression compared with supernatants of unchallenged mast
cells after 10 min (Fig. 6). Remarkably, this increase was
suppressed by more than half by the S1P3 inhibitor TY-52156
(Fig. 6). Mass spectrometry of the identical supernatants revealed
that S1P had been released (90±41 pmol S1P per 106 mast cells)
resulting in a 64.73±7.95 nM S1P concentration in the mast cell
supernatants that the HUVEC had been exposed to. Another
proof of biologically active S1P being present in the mast cell
supernatants was their ability to activate Erk MAPK in S1P1-
overexpressing CHO cells and the inhibition thereof by a S1P1
antagonist (Supplementary Fig. 7).
Rolling is increased in endothelial S1P1 deficiency. Finally, we
examined leukocyte rolling in mice deficient for the
endothelial S1P1 receptor (S1P1SCL-Cre-ERT) and observed
it to be increased compared with respective controls (Fig. 7a).
Furthermore, administration of FTY720 reduced rolling in
S1P1SCL-Cre-ERT mice to the same lower than basal levels observed
with FTY720 in control mice and C57Bl6 mice, respectively, and
S1P3 / mice (Fig. 7b). Microvascular and haemodynamic
parameters as well as rolling velocities were unaffected (Table 1
and Supplementary Fig. 1). Interestingly,
the highly specific S1P1 agonist AUI 954 (ref. 48) inhibited
forskolin-induced C17-S1P generation in HUVEC in vitro
along with inhibiting cAMP generation (Supplementary Fig. 8).
These results suggest that S1P1 negatively regulates cAMP-
stimulated Sphk1 and by reducing S1P generation possibly
inhibits P-selectin-dependent rolling, hence acting as an oppo-
nent to S1P3.
Discussion
Our study reveals the following six important and novel findings
(Fig. 8): (1) we provide evidence that S1P is a direct agonist of
P-selectin mobilization and leukocyte rolling; (2) we identify S1P3
as the major responsible S1P receptor; (3) we show that several
P-selectin agonists employ S1P and S1P3 as mediators of their






















































































Figure 4 | S1P3 and Sphk1 mediate in part the effect of histamine on P-selectin mobilization and leukocyte rolling. (a) HUVECs were stimulated with
two histamine concentrations (0.25 and 25mM) in the presence or absence of SKi (25mM) or SKiþ S1P (1 mM) for 5 min as indicated, and cell surface
P-selectin was measured by flow cytometry. Data shown are from three independent experiments. (b) HUVECs were stimulated with histamine (0.25mM)
in the presence or absence of the S1P3 inhibitor TY-52156 (10mM) and P-selectin was analysed by flow cytometry. Data are from five independent
experiments. (c) Leukocyte rolling was quantified in postcapillary venules of the cremaster muscle of Sphk1 / mice and controls (n¼4 per group).
P-selectin-blocking antibody was injected to confirm rolling dependence on P-selectin. Quantitative data are presented as mean±s.e.m. Significance was
established using a paired two-tailed Student’s t-test or a Wilcoxon rank sum test.*Po0.05; *Po0.05; ***Po0.001.
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characterize a novel cAMP-dependent mechanism of Sphk1
activation and P-selectin mobilization; (5) we identify a rolling-
inhibitory effect of endothelial S1P1; and (6) we show that
pharmacological inhibition or downregulation of S1P3 for
example by FTY720 attenuates leukocyte rolling in a physiolo-
gical setting. Only few studies have addressed S1P in the context
of processes related to leukocyte rolling: (1) S1P has been
demonstrated to both induce and inhibit the exocytosis of von
Willebrand factor through different pathways49; (2) Sphk1 was
suggested to play no role in basal leukocyte rolling but to promote
rolling after exogenous histamine administration16; (3) although
S1P promoted firm neutrophil adhesion in vitro50, neutrophil
recruitment was inhibited during acute inflammatory lung injury
in S1P lyase-deficient mice51, with S1P lyase inhibitors52 and by
S1P administration53, respectively, and (4) FTY720 was shown to
suppress neutrophil recruitment in several disease models3,53,54.
This has made general conclusions on the role of S1P and its
receptors in leukocyte rolling or their mode of action rather
difficult.
Our findings add some new evidence that helps to better
understand the role of S1P in rolling. First, it is crucial to
distinguish acute S1P effects on pre-stored P-selectin occurring
within minutes from S1P effects on cytokine-induced P-selectin
transcription that takes hours. Second, the acute S1P effects on
P-selectin are different from those caused by continuous
exposure to high S1P levels or the lack of S1P receptors. Third,
the effects of S1P analogues such as FTY720 may differ
considerably from the effects of genuine S1P at the receptor
level55. In respect to rapid P-selectin mobilization, we have clearly
shown that S1P is a direct P-selectin agonist and leads to
increased P-selectin-dependent leukocyte rolling within minutes
of its direct administration into the circulation. It is known that
despite the high amounts of S1P already present in the blood,
intravascular injection of S1P can still cause functional effects on
the endothelium such as attenuation of vascular leakage,
vasodilatation and protection against reperfusion injury53,56,57.
Accordingly, the reduced leukocyte rolling we observed after
pharmacological S1P3 inhibition and in S1P3 / mice,
respectively, are strong arguments for the causal and
direct positive contribution of endothelial S1P signalling to
P-selectin-dependent leukocyte rolling. However, we have also
found evidence that endothelial S1P1 plays an opposite role in
rolling as its deletion led to a rolling increase. However, the
pro-rolling effect of S1P3 appears to be dominant over the
anti-rolling effect of S1P1 as the net effect of acute intravascular
S1P administration in wild-type mice (where both receptors
are being engaged) was an overall increase in rolling. However, in
the absence of S1P3, anti-rolling effects of S1P1 may also
contribute to the reduction in rolling. In fact, there was a
minor but significant increase in rolling with FTY720 in S1P3
deficiency that may have occurred because of S1P1
downregulation by FTY720. Accordingly, in the absence of
endothelial S1P1, the increase in rolling may be due to a
combination of the loss of anti-rolling S1P1 effects and the still
intact and potent pro-rolling S1P3 effects. Indeed, in S1P1 /
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Figure 5 | Epinephrine and forskolin stimulate P-selectin mobilization and leukocyte rolling through adenylate cyclase/cAMP-dependent Sphk1
activation and engagement of S1P3. HUVECs were stimulated with (a) epinephrine (9 mM) in the presence of IBMX (100mM) and (b) forskolin (10mM)
with or without the S1P3 inhibitor TY-52156 (10 mM), and P-selectin was analysed by flow cytometry. Data shown are from five independent experiments.
(c) HUVECs were stimulated with forskolin (10mM) in the presence of C17-sphingosine for 30 min, washed and analysed for intracellular C17-S1P
using mass spectrometry. Data shown are from four independent experiments. (d) HUVECs were stimulated with forskolin (10 mM) or cpt-cAMP (0.3 mM)
in the presence or absence of SKi (25mM) for 30 min. P-selectin was analysed by flow cytometry. Data shown are from five independent experiments. (e)
Leukocyte rolling in C57Bl6 mice treated with forskolin or vehicle (n¼ 5 per group). Quantitative data are presented as mean±s.e.m. Significance was
established using a paired two-tailed Student’s t-test or a Wilcoxon rank sum test. *Po0.05.
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We have identified two possible sources of endogenous S1P
involved in P-selectin mobilization in our model: interstitial mast
cells and endothelial cells (Fig. 8). Interstitial mast cell activation
following mechanical cremaster muscle manipulation is entirely
responsible for the leukocyte rolling occurring there, and histamine
release accounts for B50% of it (ref. 29). As S1P can be released by
allergically activated mast cells45, and physical stimuli such as
pressure and heat can activate mast cells46,47, we hypothesized that
S1P may be another mast cell product contributing to the remaining
part of leukocyte rolling. The physical stimulus we employed to test
this in mast cells was a short, harmless temperature elevation46,47.
Indeed, we found them to release S1P within minutes that mobilized
P-selectin in HUVEC in part in a S1P3-dependent manner.
Whether this occurs in vivo and actually contributes to leukocyte
rolling in our model should be addressed by future studies.
Although platelets are the major source of P-selectin, elaborate
studies have shown that platelet P-selectin does not play a role in
leukocyte rolling58,59, and, in our hands, S1P had no effect on basal
or thrombin-stimulated P-selectin in platelets; neither was platelet
activation altered in Sphk1 / mice (Supplementary Fig. 9).
We have identified endothelial cells as the second source of
endogenous S1P capable of inducing P-Selectin mobilization.
Sphk1 activation has been known to occur after stimulation with

























































Figure 6 | Supernatants of activated mast cells stimulate P-selectin mobilization in HUVEC in a S1P3-dependent manner. (Top) FACS analysis of mouse
peritoneal mast cells (CD45þ Lin CD117þ Sca-1þ CD16/32þ CD34þ ) used for stimulation. (Bottom) HUVECs were stimulated with supernatants of
heat-activated peritoneal mast cells for 10 min in the presence or absence or the S1P3 inhibitor TY-52156 (10 mM). Diphenhydramine
and cimetidine (10mM each) were present in all experiments. P-selectin was measured using flow cytometry. Quantitative data are presented as
mean±s.e.m. for three independent mast cell preparations and three independent HUVEC preparations. Significance was established using a paired































































Figure 7 | Leukocyte rolling is increased in endothelial-specific S1P1 knockout mice (S1P1
SCL-Cre-ERT). (a) Leukocyte rolling was quantified in
postcapillary venules of the cremaster muscle of S1P1
SCL-Cre-ERT mice (Creþ and Cre , n¼ 9 per group). Rolling was also measured after systemic
injection of a P-selectin-blocking antibody (n¼4 per group). (b) Leukocyte rolling after administration of 1.25 mg kg 1 i.p. FTY720 30 min before the
experiment in both genotypes (Creþ n¼4, Cre n¼ 3). Quantitative data are presented as mean±s.e.m. Significance was established using a Wilcoxon
rank sum test. *Po0.05; *Po0.05; ***Po0.001.
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by which it contributes to rolling has remained unclear16. We
provide evidence that S1P produced by histamine-activated Sphk1
contributes to full-blown histamine mobilization of P-selectin
through S1P3. The evidence stems from two observations: (1) the
partial inhibition of P-selectin mobilization after histamine by the
blockade of Sphk1 or S1P3 and (2) the elimination of the inhibitory
effect of Sphk1 blockade on P-selectin by exogenous S1P.
Coincidently, the S1P3 receptor, the H1 histamine receptor and
the thrombin PAR-1 receptor41 not only all mobilize P-selectin but
also couple to Gq; on the other side, pharmacological Gq inhibition
has been shown to inhibit P-selectin exocytosis at least in
platelets60. This offers a plausible explanation of why S1P3 effects
have gone unnoticed in experiments employing H1 blockers or Gq
inhibitors. Our finding that endothelial-specific Gq/11 / mice
have reduced P-selectin-dependent leukocyte rolling can certainly
be explained by the blockade of several Gq-coupled receptors
including S1P3. Indeed, all these agonists have their own S1P-
independent pathways of inducing P-selectin as neither S1P3 nor
Sphk1 deletion/inhibition was able to completely inhibit P-selectin
mobilization. However, part of the histamine effect can be
attributed to S1P3. Our observation that rolling could not be
reduced any further by pharmacological S1P3 inhibition in
Gq/11 / mice argues that Gq mediates the pro-rolling effect
of S1P3. The site of action of S1P released by interstitial mast cells
or by endothelial cells exposed to histamine from the same mast
cells would primarily be on the abluminal side of the vascular
endothelium. This complies with an oriented signalling mode as
the abluminal side should be reached first by any locally released
interstitial agents. This scenario is in line with the dynamic
signalling model proposed by Camerer et al.7 of how abluminal
S1P signalling maintains endothelial integrity despite high S1P
levels in blood.
We were also intrigued by the observation that not only
histamine but another P-selectin-mobilizing agonist such as
epinephrine41 that couples with Gs and not Gq employed Sphk1
and S1P3 for full-scale P-selectin mobilization (Fig. 8). We have
demonstrated that epinephrine also activated Sphk1 but through a
cAMP-dependent mechanism and — similar to histamine — also
employed S1P and S1P3 to help mobilize P-selectin. Indeed, direct
stimulation of Sphk1 by forskolin (as measured by the conversion
of C17-sphingosine to C17-S1P) mobilized P-selectin through S1P3
in vitro and induced leukocyte rolling in vivo. In agreement with a
role for cAMP, forskolin has been shown to activate Sphk1 in
pheochromocytoma cells years ago42. However, S1P3 or Sphk1
inhibition did not completely abrogate the effects of epinephrine or
forskolin, suggesting that there must be additional pathways of
how cAMP mobilizes P-selectin41. Interestingly, the pathway of
cAMP-stimulated Sphk1 provides a putative mechanism of how
S1P1, with its established inhibitory effect on cAMP generation4,
may be exerting its antirolling effect. Indeed, the highly specific
S1P1 agonist AUI 954 (ref. 48) inhibited C17-S1P generation after
forskolin along with lowering cAMP (Supplementary Fig. 8). This
suggests that S1P1 may be attenuating cAMP-induced Sphk1
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Figure 8 | The role of S1P and its receptors in P-Selectin mobilization. Schematic representation of the direct and indirect roles S1P plays in P-selectin
mobilization. Mast cells release both histamine and S1P that can both mobilize P-selectin independently through the H1 and S1P3 receptor, respectively.
However, histamine achieves full scale P-selectin mobilization by additional Gq-dependent activation of Sphk1, S1P production/release and subsequent
activation of S1P3. Other P-selectin mobilizing agents such as epinephrine that require cAMP for P-selectin mobilization also employ Sphk1 for full-blown
effect but do so through a Gs/AC/cAMP-dependent pathway. S1P1 plays an inhibitory effect on P-selectin-dependent rolling by reducing AC-induced Sphk1
activity through Gi. DOP and pFTY720 act in an inhibitory manner on rolling by downregulating S1P1 and S1P3, but in addition, pFTY720 directly inhibits the
Gq-dependent part of S1P-incuded S1P3-dependent P-selectin mobilization. In summary, the pro-rolling effect of S1P3 dominates over the anti-rolling of
S1P1, and the net effect of acute S1P exposure is an overall increase in P-selectin-dependent leukocyte rolling. AC, adenylate cyclase; AUY 954, S1P1-specific
agonist; b2AR, b2 adrenergic receptor; DOP, the S1P lyase inhibitor 4-deoxypyridoxine; H1, H1 histamine receptor; PSGL, P-selectin glycoprotein ligand-1;
Sphk1, sphingosine kinase 1; TY-52156, S1P3-specific inhibitor.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7416 ARTICLE
NATURE COMMUNICATIONS | 6:6416 | DOI: 10.1038/ncomms7416 | www.nature.com/naturecommunications 9
& 2015 Macmillan Publishers Limited. All rights reserved.
amounts of S1P available for P-selectin mobilization by S1P3. The
reduced leukocyte rolling we have observed in Sphk1 / mice is
in line with Sphk1/S1P serving as a general transmission/
amplification hub for different incoming P-selectin mobilization
signals. While the S1P1 receptor has often been implicated in
Sphk1 signalling, there is to our knowledge only scarce evidence
for an involvement of S1P3 in conveying Sphk1 signals: only one
study has implied S1P3 as a mediator of thrombin-induced Sphk1
effects in dendritic cells61. The requirement of S1P3 for full
efficiency of several P-selectin agonists may also serve another
purpose: S1P3 downregulation or desensitization after engagement
by endogenous S1P may help ameliorate excessive P-selectin
stimulation and help turn it off.
Acute S1P effects on P-selectin mobilization should be
distinguished from those caused by continuous exposure to S1P
or S1P analogues. High S1P levels after S1P lyase inhibition or
deficiency and administration of FTY720 have been shown to
downregulate S1P receptors1,62,63 including S1P3 (ref. 64) and
impair lymphocyte trafficking. Accordingly, the reduced
neutrophil recruitment found in S1P lyase-deficient mice51 or
after FTY720 treatment53,54 may be due to downregulation of
S1P3. In line with this, we have observed that FTY720 had no
additional inhibitory effect on rolling in S1P3 / mice.
However, another mechanism may also be involved: we have
previously shown that pFTY720 is a potent inhibitor of Gq-
mediated S1P-induced S1P3 signalling39. In the present study, we
extended this observation to P-selectin mobilization by S1P3.
Thus, both mechanisms could be taking place simultaneously as:
(1) preincubation with pFTY720 abolished S1P-induced
P-selectin mobilization in endothelial cells as well as S1P3-
dependent S1P signalling in S1P3-CHO cells; (2) pFTY720 had
a minor and very short-lived positive effect on P-selectin
compared with S1P, while (3) its simultaneous application
together with S1P abolished P-selectin mobilization by S1P. In
line with this interpretation, another P-selectin-dependent
process, the recruitment of early thymic progenitors to the
thymic endothelium, has been shown to be inhibited by FTY720
(ref. 65), although the responsible receptor was not identified.
In summary, our study suggests an important role for S1P and
S1P3 in the induction of rapid endothelial P-selectin mobilization
and consecutive P-selectin-dependent leukocyte rolling. S1P
acts thereby both directly as an agonist and, indirectly, as a
contributor to P-selectin mobilization by other P-selectin
agonists.
Methods
Mice. S1P3 / mice were provided by Jerold Chun, Scripps Research Institute to
B.L. and crossbred to C57Bl6J for more than six generations. Sphk1 / mice were
provided to M.H.G. by Richard Proia (NIH) and Tie2-Cre-ER(T2); Gaqflox/flox;
Ga11 / were from S.O. Mice deficient for the endothelial S1P1 receptor were
generated by crossbreeding S1P1flox/flox mice66 with endothelial-SCL-Cre-ERT mice,
in which the tamoxifen-inducible Cre-ERT recombinase is driven by the
50-endothelial enhancer of the stem cell leukaemia (SCL) locus67 (Supplementary
Fig. 11). Cre-negative S1P1SCL-Cre-ERT littermates treated with the same tamoxifen
regimen were used as controls. Recombination was induced by daily intraperitoneal
injections of tamoxifen (40 mg per kg body weight) for five consecutive days, and
the experiments were performed 6 weeks later. Successful recombination was
shown in lung endothelial cells isolated using CD31-coated magnetic beads
(Dynabeads) by site-specific PCR for the excised exon. All mice used in the study
were male and at least 10 weeks of age. All procedures were performed in
accordance with the institutional guidelines for health and care of experimental
animals and were approved by the Regierung von Baden Württemberg and
Oberbayern, respectively.
Substances and antibodies. S1P was purchased from Enzo Life Science. The S1P3
inhibitors TY-52156 (Supplementary Fig. 2) and FTY720 were synthesized as
described32. AUY 954 was a kind gift from Klaus Seuwen (Novartis). In vivo,
FTY720 and TY-52156 were applied intraperitoneally at 1.25 mg per kg and
forskolin at 1.3 mg per kg body weight 30 min or 24 h before the experiment as
indicated. S1P was injected via a carotid artery catheter at 30 mg per kg body
weight (125 mM S1P solution in 2% BSA per 0.9% NaCl). The S1P lyase inhibitor
DOP (Sigma Aldrich) was supplemented in the drinking water (30 mg l 1) for
1 week. W146 and C17 sphingosine were from Avanti polar lipids, the
SKi 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]-phenol (SKi, SKI II and SPHK I2),
pFTY720, SEW2871 and U73122 from Cayman Chemical Co; epinephrine from
Sanofi Aventis; forskolin from Calbiochem; IBMX, cpt-cAMP, diphenhydramine
and cimetidine from Sigma Aldrich; and thapsigargin from AppliChem. S1P1-CHO
and S1P3-CHO cells were from Novartis. The following antibodies were used:
CD62P-PE (phycoerythrin) anti-mouse (eBioscience, 12-0626-82, 3:100),
CD4-PE anti-mouse (eBioscience, 12-0041, 1:100), CD8-PE anti-mouse
(eBioscience, 12-0081, 1.4:100), Ter119-PE anti-mouse (Miltenyi, 130-091-783,
3:100), Ly6G&Ly6C-PE anti-mouse (BD Pharmingen, 553128, 1.6:100), CD45R-PE
anti-mouse (BD Pharmingen, 553089, 1.6:100), CD34-AlexaFluor700 anti-mouse
(BD Pharmingen, 1.6:100), CD16/32-PerCpCy5.5 anti-mouse (BD Pharmingen,
560540, 1.65:100), LyA/E-FITC anti-mouse (BD Pharmingen, 557405, 1.1:100),
CD117-PE-Cy7 anti-mouse (BD Pharmingen, 558163, 1.7:100), CD450-V450
anti-mouse (BD Pharmingen, 560697, 1.8:100) and P-selectin glycoprotein ligand-
1-PE anti-mouse (BD Pharmingen, 555306, 1:1,000). The P-selectin-blocking
rat-anti-mouse monoclonal antibody RB40.34 was a generous gift from Dietmar
Vestweber (MPI Münster).
Flow chamber assay for rolling on immobilized P-selectin. Rectangular glass
capillaries (0.4 0.04 mm, VitroCom) were used for ex vivo flow chamber
experiments as described31. Chambers were coated with recombinant murine
(rm)P-selectin (CD62-P, 20 mg ml l, R&D Systems). Following overnight
incubation at 4 C, flow chambers were blocked with 5% casein (Sigma-Aldrich) in
PBS for 2 h. For experiments, one end of the chamber was attached to a carotid
artery catheter, while the other was left open to regulate blood flow through the
microflow chamber. Microscopy was performed using a modified Olympus BX51
upright microscope (LaVision Biotec) with a saline immersion objective (40/0.8
numerical aperture (NA), Olympus). Leukocyte rolling was recorded over 10 min
per microflow chamber with a CCD (charge-coupled device) video camera (model
CF8/1; Kappa) connected to a Panasonic S-VHS recorder and analysed offline.
Intravital microscopy of the cremaster muscle. Intravital microscopy of post-
capillary venules of the mouse cremaster muscle was used to study leukocyte rolling
under different inflammatory conditions25,27. Briefly, mice were anaesthetized by
intraperitoneal injection of ketamine and xylazine (100 and 20 mg per kg body
weight, respectively), after which a tracheal tube was inserted and the carotid artery
cannulated for blood sampling and systemic application of substances. Thereafter,
the scrotum was opened, the cremaster muscle exteriorized, spread over a cover
glass and superfused with warmed (35 C) bicarbonate-buffered saline. Observation
of postcapillary venules was conducted on an upright microscope (Olympus BX51)
with a saline immersion objective ( 40/0.8 NA). To abolish P-selectin-dependent
rolling, the P-selectin-blocking monoclonal antibody RB40.34 (30 mg per mouse)
was diluted in 200 ml saline and injected via the carotid artery catheter. Experiments
were recorded via a CCD camera system (model CF8/1; Kappa) on a Panasonic
S-VHS recorder. Systemic blood samples (10 ml) were obtained before and during
the experiment, stained using Turck’s solution and assessed for white blood cell
count using a haemocytometer. Data analysis was performed offline using the video
tapes from in vivo experiments. Diameter, segment length of postcapillary venules
and venular centreline blood flow velocity were assessed using a digital image-
processing system and a digital online cross-correlation programme, respectively
(Circusoft Instrumentation)24. Leukocyte rolling flux fraction was calculated from
the number of rolling cells that crossed a perpendicular line through a given vessel
within 1 min in relation to the total number of circulating leukocytes.
Whole-mount immunohistochemistry. For immunohistochemical detection of
luminal endothelial P-selectin expression in cremaster muscle whole mounts,
primary monoclonal antibody against P-selectin RB40.34 (30 mg per mouse) was
systemically injected after 20-min superfusion of the exteriorized right cremaster
muscle ensuring binding to P-selectin on the luminal vessel surface. To remove
excess antibody, the inferior vena cava was cut and animals were perfused with
10 ml of 0.9% NaCl. The left cremaster muscle was exteriorized post mortem to
serve as unstimulated negative control. The cremaster muscles were then mounted
on adhesive slides (Superfrost), transferred into  20 acetone over night and
stored at  80 C until further processing. For staining of P-selectin expression,
cremaster whole mounts were permeabilized with saponin (0.03% in Tris-buffer)
and incubated with 2 mg ml l biotinylated secondary goat anti-rat IgG (Southern
Biotechnology Associates Inc, Cat. No 3030-08). Detection of antigen–antibody
complexes was carried out with a commercial biotinylated horseradish peroxidase/
avidin complex (Vectastain ABC, Vector Laboratories) according to the manu-
facturer’s instructions. Slides were counterstained using Mayer’s Hemalaun and
analysed using a Zeiss microscope with a  100, 1.4 NA oil immersion objective.
P-selectin mobilization in HUVEC. HUVECs (passage 1–4) were cultured in 20%
human serum/RPMI. After incubation in serum-free medium for 4 h, cells were
stimulated with histamine (0.25 or 25 mM), S1P (1mM), SEW2871 (1 mM) and
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epinephrine (9mM)/IBMX (100 nM), respectively, for the indicated times. Before
histamine or S1P stimulation, the S1P3 inhibitor TY-52156, SKi or phosphorylated
FTY720 (10mM) were added for 30 min; with forskolin, inhibitors were added
10 min before stimulation. Five minutes before the end of the experiment, PE-
conjugated anti-P-selectin antibody (eBioscience; 1.6:100) was added directly into
the 500ml of incubation medium after which the cells were washed twice and
analysed immediately by flow cytometry.
Stimulation with supernatants of activated mast cells. Mouse peritoneal mast
cells were isolated by a Percoll gradient as described68 and characterized as
CD45þ , Lin (CD45R, Ly6G, Ly6C, Ter119, CD4 and CD8), CD117þ , Sca-1þ ,
CD16/32þ and CD34þ cells by flow cytometry and consecutive toluidine blue
staining68,69. The yield was 0.05–0.1 106 mast cells per mouse. All peritoneal cells
were incubated with 10 mM sphingosine for 30 min at 37 C before the Percoll
gradient isolation procedure. Stimulation was performed by adding 250 ml warm
(53 C) 2% BSA/alphaMEM to 0.5 106 mast cells and subsequent incubation for
2 min at 53 C as described46,47. For stimulation of HUVEC, 100ml of the mast cell
supernatant was supplemented with diphenhydramine and cimetidine (10mM
each) and added to confluent HUVEC cultured in 200ml RPMI for 10 min. PE-
conjugated anti-P-selectin antibody was added directly into the 300 ml at the time
of stimulation. Cells were washed twice with serum-free medium, trypsinized and
analysed by flow cytometry.
Measurements of Sphk1 activity using C17-sphingosine. Five mM C17-sphin-
gosine was added together with 10 mM forskolin to HUVEC in RPMI with 2 mg per
ml BSA fraction V (Serva) for 30 min. Cells were washed extensively and lysed in
50 mM Tris/HCl (pH 7.5), 0.5%NP-40, 10% glycerol, 250 mM NaCl, 5 mM EDTA,
0.5 mM phenylmethyl sulphonyl fluoride, 5 mg ml l leupeptin and aprotinin.
Protein concentration was measured using the Pierce BCA Protein Assay Kit
(Thermo Scientific). C17-S1P was determined by mass spectrometry as described70
and expressed per milligram cell protein.
Statistics. For pair-wise comparison between experimental groups, a Wilcoxon
rank sum test or paired Student’s t-test was performed. For multiple comparisons, a
Kruskal–Wallis nonparametric analysis of variance on ranks was performed fol-
lowed by Dunn’s post hoc test. A P valueo0.05 was considered statistically sig-
nificant. All statistical analyses were carried out with GraphPad Prism 5.2
(PraphPad Software Inc, La Jolla). Data are presented as mean±s.e.m. Sample size
has been provided for each experiment in the figure legend (no exclusion criteria,
randomization or blinding).
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